Press
-
SRI teams with Kalekona Radiotheranostics to deliver breakthrough therapies aimed at diagnosing and treating pancreatic cancer and glioblastoma
SRI’s FOX Three peptide platform to deliver precision radionuclide therapy targeted at hard-to-treat tumors.
-
SRI multi-party team selected as an awardee by ARPA-H to develop at-home screening for ≥30 types of cancers
The POSEIDON program aims to save millions of lives by detecting cancer early.
-
Encryption where it counts
Confidencial, an SRI spinout, is breaking new ground in helping industry and government clients secure highly sensitive data.
-
PARC Forum: The future of trust
Mitchell Baker and Mariano-Florentino “Tino” Cuéllar discuss the global imperative of safe, human-first AI.
-
Christiana McFarland: From strategy to impact in a technology-driven world
At SRI’s Center for Innovation Strategy and Policy, McFarland guides governments and regions toward ecosystems that transform technological change into sustainable growth.
-
N4 Pharma and SRI demonstrate breakthrough in RNA cancer therapy
The collaboration paves the way for increased precision in cancer treatment.
-
SRI charts the future of bioscience in Arizona
Working with the Flinn Foundation, SRI created a roadmap that will guide Arizona’s ongoing transformation into a national bioscience hub.
-
What’s next in AI-based translation?
Reviewing the Apple AirPods Pro 3, The New York Times turned to SRI’s Dimitra Vergyri to unpack the significance of recent advances in translation tech.
-
Can AI help kids learn more from online videos?
Kids watch a lot of online videos. SRI is exploring how machine learning could steer that screen time toward positive learning outcomes.
-
Self-Cooling Paint is on a roll
SRI’s cooling solution garners media attention and commercial interest.
-
PARC Forum: The future of education in the age of AI
Leading voices on AI in education explore how AI can advance teaching and learning.
-
Podcast: A peer-based approach to learning acceleration
SRI’s Adrienne Woods joins AIR’s Alida Hudson to discuss the development and impact of PALS-RD.